LEGAL GUIDES FOR INVESTORS
If you suffered losses in SCYNEXIS stock, contact SCYNEXIS stock loss lawyer Timothy L. Miles about a SCYNEXIS class action lawsuit
INTRODUCTION TO THE SCYNEXIS CLASS ACTION LAWSUIT
The SCYNEXIS class action lawsuit seeks to represent purchasers or acquirers of SCYNEXIS, Inc. (NASDAQ: SCYX) securities between March 31, 2023 and September 22, 2023, inclusive (the “Class Period”). Captioned Feldman v. SCYNEXIS, Inc., No. 23-cv-22082 (D.N.J.), the SCYNEXIS class action lawsuit charges SCYNEXIS and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
If you suffered losses in SCYNEXIS stock and wish to serve as lead plaintiff in the SCYNEXIS class action lawsuit, please contact SCYNEXIS Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected] or by submitting a contact form. Lead plaintiff motions for the SCYNEXIS class action lawsuit must be filed with the court no later than January 8, 2024.
Read on to learn answers to five frequently asked questions about the SCYNEXIS class action lawsuit.
what are the ALLEGATIONS IN THE SCYNEXIS CLASS ACTION LAWSUIT?
The SCYNEXIS class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination; (ii) SCYNEXIS did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices; and (iii) due to the substantial risk of cross-contamination, SCYNEXIS was reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies.
The SCYNEXIS class action lawsuit further alleges that on September 25, 2023, SCYNEXIS revealed that following a recent review by GSK plc of the manufacturing process and equipment at the vendor that manufactures the ibrexafungerp drug substance, SCYNEXIS became aware of potential cross contamination of ibrexafungerp with a non-antibacterial beta-lactam drug substance. SCYNEXIS declared it would conduct a recall of BREXAFEMME from the market and place a temporary hold on clinical studies of ibrexafungerp, including a Phase 3 clinical study, until a mitigation strategy and a resupply plan are determined, according to the complaint. The SCYNEXIS class action lawsuit alleges that on this news, the price of SCYNEXIS stock fell more than 41% over two trading sessions.
CAN I BE APPOINTED LEAD PLAINTIFF IN THE SCYNEXIS CLASS ACTION LAWSUIT IF I PURCHASED SHARES OUTSIDE OF THE CLASS PERIOD?
No. Even if you suffered losses in SCYNEXIS stock, if you purchased securities outside of the Class period, you will not be able to participate in the SCYNEXIS class action lawsuit.
CAN A NON-U.S. INVESTOR SERVE AS LEAD PLAINTIFF IN THE SCYNEXIS CLASS ACTION LAWSUIT IF THEY SUFFERED LOSSES IN SCYNEXIS STOCK?
Yes, courts in the U.S. have consistently recognized that non-U.S. investors, many of whom have substantial holdings, are adequate lead plaintiffs and have the same right to move for lead plaintiffs as U.S. investors. Thus, if a non-U.S. investor suffered losses in SCYNEXIS stock, they may move the Court to be appointed lead plaintiff in the SCYNEXIS class action lawsuit.
WILL THE LEAD PLAINTIFFS GET MORE MONEY THAN CLASS MEMBERS IF THE SCYNEXIS CLASS ACTION LAWSUIT?
No, but they may be entitled to recover their reasonable expenses incurred with are directly related to representing the class in the SCYNEXIS class action lawsuit. Under the Private Securities Litigation Reform Act of 1995, a Lead Plaintiff is only entitled to his or her pro rata share of any recovery and does not receive any additional money for serving as a representative party on behalf of the class. However, a court, in its discretion, may approve an award of “reasonable costs and expenses (including lost wages)” to a Lead Plaintiff that directly relates to the representation of the class in the SCYNEXIS class action lawsuit on behalf of investors who suffered losses in SCYNEXIS stock.
CAN THE COURT APPOINT MORE THAN ONE LEAD PLAINTIFF IN THE SCYNEXIS CLASS ACTION LAWSUIT?
Yes, at its discretion the Court may appoint a person, entity, or group of persons and/or entities as Lead Plaintiffs to oversee the SCYNEXIS class action lawsuit.
CONTACT A SCYNEXIS STOCK LOSS LAWYER TODAY IF YOU SUFFERED LOSSES IN SCYNEXIS STOCK ABOUT A SCYNEXIS CLASS ACTION LAWSUIT
If you suffered losses in SCYNEXIS Cell stock, contact SCYNEXIS stock loss lawyer Timothy L. Miles today for a free case evaluation about a SCYNEXIS class action lawsuit. Call today and see what a SCYNEXIS stock loss lawyer could do for you if you suffered losses in SCYNEXIS Cell stock.
SCYNEXIS stock loss lawyer Timothy L. Miles
Nashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, 6Class Action: Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America's Most Honored Lawyers 2020; Top 1% by America's Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime.
The Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr., #247
Brentwood, TN 37027
Phone: (855) 846-6529
Email: [email protected]
HOURS OF OPERATION